Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

@article{MoralesBarrera2012CisplatinAG,
  title={Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.},
  author={Rafael Morales-Barrera and Joaquim Bellmunt and C. Su{\'a}rez and Claudia Valverde and Marta Guix and C{\'e}sar Ruiz Serrano and Manuel Gall{\'e}n and J Carles},
  journal={European journal of cancer},
  year={2012},
  volume={48 12},
  pages={1816-21}
}
BACKGROUND Cisplatin-based combination chemotherapy is the mainstay of treatment for locally advanced or metastatic urothelial carcinoma. However, standard dose schedule of cisplatin cannot be used in patients with impaired renal function. We evaluated the safety and efficacy of gemcitabine and a split dose administration of cisplatin in patients with renal… CONTINUE READING